Simplification of Complex Physiologically Based Pharmacokinetic Models of Monoclonal Antibodies

No abstract is available for this paper.

• Publication year

  2014

• Venue

  AAPS Journal

• Publication date

  2014-05-29

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1208/s12248-014-9591-xPMID 24871341PMCID PMC4070266
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies

  2013cited by this paper
• Antibody therapy of cancer

  2012cited by this paper
• In Search of Physiologically Based Distribution Volume Estimates for Macromolecules

  2012cited by this paper
• Evaluation of a Catenary PBPK Model for Predicting the In Vivo Disposition of mAbs Engineered for High-Affinity Binding to FcRn

  2012cited by this paper
• Application of PBPK modeling to predict monoclonal antibody disposition in plasma and tissues in mouse models of human colorectal cancer

  2012cited by this paper
• Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human

  2012cited by this paper
• Marketed therapeutic antibodies compendium

  2012cited by this paper
• Applications of minimal physiologically-based pharmacokinetic models

  2012cited by this paper
• Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response models

  2011cited by this paper
• Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease

  2010cited by this paper
• [Antibody therapy in cancer].

  2010cited by this paper
• Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease

  2010cited by this paper
• Population Pharmacokinetics of Therapeutic Monoclonal Antibodies

  2010cited by this paper
• Development and Validation of an Enzyme Linked Immunosorbent Assay for the Quantification of Carcinoembryonic Antigen in Mouse Plasma

  2009cited by this paper
• Monoclonal Antibody Pharmacokinetics and Pharmacodynamics

  2008cited by this paper
• Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice

  2007cited by this paper
• Quasi-Equilibrium Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition

  2005cited by this paper
• Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level.

  2004cited by this paper
• Pharmacokinetic aspects of biotechnology products.

  2004cited by this paper
• Assuming Peripheral Elimination: Its Impact on the Estimation of Pharmacokinetic Parameters of Muscle Relaxants

  1999cited by this paper
• Lumping of Whole-Body Physiologically Based Pharmacokinetic Models

  1998cited by this paper
• Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model.

  1995cited by this paper
• Interference by human and bovine serum and serum protein fractions with the absorption of antibodies by suckling rats and mice

  1958cited by this paper

• Predicting Human Subcutaneous Bioavailability of Therapeutic Monoclonal Antibodies from Systemic Clearance and Volume of Distribution.

  2024cites this paper
• Improving priors for human monoclonal antibody linear pharmacokinetic parameters by using half-lives from non-human primates

  2021cites this paper
• Whole-Body Physiologically Based Pharmacokinetic Modeling of Trastuzumab and Prediction of Human Pharmacokinetics.

  2019cites this paper
• MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issues

  2018cites this paper
• Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model.

  2018cites this paper
• Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics

  2016cites this paper
• Physiologically Based Pharmacokinetic ( PBPK ) Modeling and Simulation Approaches : A Systematic Review of Published Models , Applications , and Model Verification s

  2015cites this paper
• Mechanistic Physiologically Based Pharmacokinetic Models in Development of Therapeutic Monoclonal Antibodies

  2015cites this paper
• Tools for predicting the PK/PD of therapeutic proteins

  2015cites this paper
• An Extended Minimal Physiologically Based Pharmacokinetic Model: Evaluation of Type II Diabetes Mellitus and Diabetic Nephropathy on Human IgG Pharmacokinetics in Rats

  2015influential citation